A study provided evidence that the combination of zerumbone (Zer) and gefitinib (Gef) in lung cancer treatment downregulates p-Akt and p-STAT3, indicating the inhibition of the AKT/STAT3 signaling axis. This evidence concerns the gene AKT1 and lung cancer.